Sees FY25 revenue $10.2B-$10.4B, consensus $10.44B.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon a launches OTC eye drop SYSTANE PRO preservative-free PF
- Positive Outlook for Alcon Amidst New Product Developments and Market Growth Potential
- Is ALC a Buy, Before Earnings?
- Alcon debuts Voyager DSLT for glaucoma and ocular hypertension treatment
- Positive Outlook for Alcon Despite Patent and Exclusivity Challenges, Driven by Product Launches and Legal Protections